MedTrace Logo

Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

NCT05781516 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2023-03-27

No results posted yet for this study

Summary

Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.

Conditions

  • IgG4-related Disease With Eosinophilia

Interventions

DRUG

Prednisolone

Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.

DRUG

Baricitinib

Oral Baricitinib 2mg daily for 12 months.

Sponsors & Collaborators

  • Tongji Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Wen Zhang

    lead OTHER

Principal Investigators

  • Wen Zhang, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-20
Primary Completion
2024-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05781516 on ClinicalTrials.gov